Literature DB >> 27517387

The therapeutic range for phenytoin - A reappraisal.

M Feeley1, B Duggan1, M O'Callagan1, N Callaghan1, J Seldrup2.   

Abstract

Serum levels of phenytoin were compared with seizure control in a prospective study of 31 patients with a wide variety of seizures of varying severity. Twenty-two patients were followed up for an average period of 15 months, and 9 for an average period of 6 months. Nine patients became seizure free (excellent control), and a greater than 50% reduction in seizure frequency occurred in 13 patients (good control). A less than 50% reduction in seizure frequency occurred in 9 patients (poor control). An excellent or good response was associated with mean levels within a therapeutic range in 9 patients, and with subtherapeutic levels in 13 patients. Only 2 patients with poor control reached mean levels within the therapeutic range. Even with frequent dose adjustments, it was impossible to achieve higher levels in this group. Patients with both mild, moderate, and severe seizures responded at levels which were both subtherapeutic and within the therapeutic range. Fluctuations of serum levels occurred in all patients, but was most marked in patients with a good response. The results show that the therapeutic range would not appear to be valid as patients responded to a wide range of levels irrespective of seizure severity.

Entities:  

Year:  1979        PMID: 27517387     DOI: 10.1007/BF02938049

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  10 in total

1.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

2.  Simultaneous determination of carbamazapine ("Tegretol") and other anticonvulsants in human plasma by gas-liquid chromatography.

Authors:  J C Roger; G Rodgers; A Soo
Journal:  Clin Chem       Date:  1973-06       Impact factor: 8.327

3.  Studies of anticonvulsant levels in epileptics. I. Serum diphenylhydantoin concentrations in a group of medically indigent outpatients.

Authors:  A F Haerer; J B Grace
Journal:  Acta Neurol Scand       Date:  1969       Impact factor: 3.209

4.  Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients.

Authors:  H Kutt; F McDowell
Journal:  JAMA       Date:  1968-03-11       Impact factor: 56.272

5.  Clinical and electroencephalographical classification of epileptic seizures.

Authors:  H Gastaut
Journal:  Epilepsia       Date:  1970-03       Impact factor: 5.864

6.  Serum-phenytoin levels in management of epilepsy.

Authors:  A Richens; A Dunlop
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

7.  Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures.

Authors:  L Lund
Journal:  Arch Neurol       Date:  1974-11

8.  Some causes of ineffectiveness of diphenylhydantoin.

Authors:  H Kutt; J Haynes; F McDowell
Journal:  Arch Neurol       Date:  1966-05

9.  Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients.

Authors:  G W Houghton; A Richens
Journal:  Br J Clin Pharmacol       Date:  1974-04       Impact factor: 4.335

10.  One drug (phenytoin) in the treatment of epilepsy.

Authors:  E H Reynolds; D Chadwick; A W Galbraith
Journal:  Lancet       Date:  1976-05-01       Impact factor: 79.321

  10 in total
  2 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Sulthiame in previously untreated epilepsy.

Authors:  M P Feely; M O'Callaghan; D O'Driscoll; N Callaghan
Journal:  Ir J Med Sci       Date:  1982-06       Impact factor: 1.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.